Furthermore, overexpression of MET was associated with significantly poorer survival outcomes, suggesting that identification of MET overexpression using IHC may provide a potential biomarker to enable the individualized treatment of patients with NPC. Here, MET is linked to nasopharyngeal carcinoma.